Should the FDA Do More to Increase Transparency?
An FDA pilot program to promote transparency in clinical studies falls short of similar efforts by its European and Canadian counterparts.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows. -
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients. -
Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen. -
Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Changes in Hematologic Parameters Following Pesticide Exposure
Poor Outcome for Patients With Multiple Myeloma Who Are Refractory to CD38-Targeting Agent
Carfilzomib Dosing and Scheduling in Newly Diagnosed Multiple Myeloma
Comparing Efficacy and Safety of Auto-HCT in Older and Younger Patients With Multiple Myeloma
The Incidence of Some Obesity-Related Cancers Is Increasing Among Young Adults
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
